Awareness • Early Detection • Treatment • Research • Survivorship

Pierre Massion, MD. Vanderbilt University

Dr. Pierre Massion is the Ingram Professor of Cancer Research. He is Professor of Medicine in the Division of Allergy, Pulmonary and Critical Care Medicine and Professor of Cancer Biology at Vanderbilt Medical Center. Dr. Massion has worked in the field of lung cancer biology, early detection and therapeutics for 16 years.

He is the director of the Thoracic Program at the Vanderbilt Ingram Cancer Center and thereby overseeing and fostering a rich environment to translate science from the program to trials in the cooperative groups. He has over 80 publications in the areas of lung cancer development, role of oncogenes in the progression of lung tumor cells and innovative strategies towards the development of molecular biomarkers for early detection of lung cancer and intermediate endpoint biomarkers of response to chemoprevention. He served as Chief of the Pulmonary and Critical Care Medicine section at the Nashville VA Medical Center between 2007-2012.

He is certified by the American Board of Internal Medicine in Internal Medicine and in Pulmonary and Critical Care Medicine. He is the principal investigator of the Vanderbilt SPORE in lung cancer and of the Vanderbilt Clinical Validation Center sponsored by the EDRN to validate candidate biomarkers of lung cancer. He is also co-PI of two DoD grants, one of which offers lung cancer screening across 12 VA and military hospitals to validate candidate biomarkers of risk and of diagnosis for lung cancer.

Dr. Massion has mentored over 19 postdoctoral fellows, 11 graduate students and 20 undergraduate students. He is committed to pursuing innovative strategies to deepen the understanding of lung cancer development and progression. His laboratory applies novel genomic and proteomic technologies to biological specimens to address questions related to the identification and validation of molecular determinants of disease diagnosis, progression, prognosis, and intermediate endpoint biomarkers of response to chemo preventive strategies. He is the PI of 6 active clinical studies –

He is the Chair of the Lung Cancer Cooperative group in the EDRN and the Chair of the Scientific Advisory Board of the largest non-profit lung cancer foundation LUNGevity. He is a contributing member to the National Comprehensive Cancer Network related Non-Small Cell Lung Cancer Guidelines committee.

Dr. Pierre Massion, Vanderbilt University from TEAM DRAFT on Vimeo.